TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Neonatal Immunization With Pneumococcal Conjugate Vaccine in Papua New Guinea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~New born babies with birth weight \>2000 g (2 kgs) and parents giving consent~Exclusion Criteria:~1. Acute neonatal infection;~2. Severe congenital abnormality;~3. Children of mothers known to be HIV positive will be excluded;~4. Serious asphyxia at birth;~5. Intended migration in the next 2 years;~6. Parents withdraw consent;

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 3 Days
- Healthy Volunteers: t

Study Arms:
- Neonatal 7vPCV (Type: EXPERIMENTAL): Receive study vaccine (Prevnar) at birth, 1 and 2 months
- Infant 7vPCV (Type: EXPERIMENTAL): Receive the study vaccine (Prevnar) at 1, 2 and 3 months
- Control (Type: PLACEBO_COMPARATOR): Do not receive study vaccine (Prevnar)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VISmodegib for ORbital and Periocular Basal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients over 18 years of age with locally advanced or recurrent orbital or periorbital basal cell carcinoma (BCCA), or a medial canthal BCCA that threatens the lacrimal drainage system.~* Clinical assessment score obtained at baseline.~* Medical Oncology screening performed at baseline.~* Adequate BCCA size and location.~* Adequate hematopoietic capacity, hepatic and renal function.~* Male patients must agree to use condoms during treatment and for 3 months after last dose.~* Male patients must agree to not donate sperm during treatment and for 3 months after last dose.~* Participant must agree not to donate blood during the study and for 7 months after last dose.~* Informed consent signed.~* If the patient consents to enroll, then blood will be drawn and stored for biomarker analysis.~Exclusion Criteria:~* Inability or unwillingness to swallow capsules.~* Inability or unwillingness to comply with study procedures.~* Pregnant, lactating, or breast feeding women.~* Women of childbearing potential.~* Uncontrolled medical illness.~* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.~* Age under 18 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vismodegib (Type: EXPERIMENTAL): 150mg taken orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of the Booster Dose of Two MenC Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy toddlers of both sexes~* Toddlers of 14 to 19 months of age (including the day that the toddler is 14 and the day before he is 19 months of age)~* Children previously vaccinated with two doses of polysaccharide meningococcal C vaccine conjugated to tetanus toxoid or three doses of polysaccharide meningococcal C conjugated to CRM197 before 7 month of age.~* Informed consent signed by one or both parents who are adequately informed about the study.~Exclusion Criteria:~* Toddlers with severe diseases or axilar temperature ≥ 38,0ºC at inclusion time~* Toddlers with severe chronic diseases~* Toddlers who have received any other vaccine within the last month or with a programmed vaccination within the 28 subsequent days after the administration of the vaccine of study.~* Toddlers with clinical or bacteriological diagnosis of previous meningococcal disease.~* Toddlers with hypersensitivity to any of the components of the vaccines to study or antibiotics used during the manufacturing process that could be present as non- detectable traces (streptomycin, neomycin, polymyxin B).~* Toddlers with personal history of convulsions.~* Toddlers with known bleeding disorder no controlled~* Toddlers with known congenital or acquired immunodeficiency~* Toddlers who are receiving or have been received any treatment that could change the immune response (administration of intravenous immunoglobulin, systemic corticosteroids or haemoderivates) within the 3 previous months.~* A toddler that under investigator opinion is probable to be lost during the follow-up~* A toddler that is currently included or is planned to be included in any other clinical trial.~* A toddler that under investigator opinion must not be included in the study due to other medical or social reasons.

- Gender: ALL
- Minimum Age: 14 Months
- Maximum Age: 19 Months
- Healthy Volunteers: t

Study Arms:
- MENC-CRM/MENC-CRM (Type: EXPERIMENTAL): Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
- MENC-CRM/MENC-TT (Type: EXPERIMENTAL): Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
- MENC-TT/MENC-CRM (Type: EXPERIMENTAL): Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
- MENC-TT/MENC-TT (Type: EXPERIMENTAL): Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~RDS Patients~1. NICU patient, ≥1hour of age and \<24 hours of age.~2. Clinical diagnosis of RDS, with or without chest X-ray data.~3. Inspired oxygen ≥21% to maintain adequate oxygen saturation.~4. Not intubated~5. Requiring:~   1. nasal continuous positive airway pressure (nCPAP).~Exclusion Criteria:~1. Congenital anomaly limiting care options or requiring early surgery.~2. Cardiopulmonary decompensation.~   1. hypotension with metabolic acidosis (base excess \< -10 meq/l).~  2. Oxygen saturations \< 88% at start of aerosolization.~  3. PaCO2 ≥ 60 mmHg at start of aerosolization.~3. Grade 3 or Grade 4 intraventricular hemorrhage by cranial ultrasound, if known.~4. Acute hypoxic encephalopathy with or without seizures.

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 24 Hours
- Healthy Volunteers: f

Study Arms:
- Aerosolized Calfactant (Type: EXPERIMENTAL): 1. NICU Patients with a clinical diagnosis of RDS~2. Inspired oxygen ≥21% to maintain adequate oxygen saturation~3. Not Intubated~4. Requiring Nasal continuous positive airway pressure
- Usual Care (Type: NO_INTERVENTION): There will be no protocol driven interventions in the usual care group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital Hollow

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has right and left infraorbital hollow (IOH) volume deficit with a rating of 2 or 3 (moderate or severe) on the MIHAS.~* Has the same MIHAS score on both IOHs (i.e., IOHs are symmetrical).~* Is at least 22 years of age.~Exclusion Criteria:~* Ever been treated with fat injections or permanent and/or semi-permanent dermal fillers in the midfacial region.~* Received lower eyelid and/or malar region treatments with any absorbable or temporary fillers such as porcine-based collagen fillers, hyaluronic acid (HA) products, RADIESSE®, poly L-lactic acid (PLLA) or received mesotherapy treatment to the area within the past 24 months or plans to receive such treatments during participation in the study.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belotero Balance® (Type: EXPERIMENTAL): None
- No treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects equal or more than 6 years of age with mild, moderate or severe hemophilia A (FVIII activity: more than 5%, 1-5%, or less than 1%, respectively)~* Subjects with previous exposure to FVIII replacement therapy~* If human immunodeficiency virus (HIV) positive, documented cluster of differentiation (CD4) count more than 200/µL within 6 months of study entry~Exclusion Criteria:~* Diagnosed with any bleeding disorder in addition to hemophilia A~* Current FVIII inhibitor or history of FVIII inhibitor (defined as positive result of the reporting laboratory)~* Subject has no history of exposure to FVIII products (previously untreated patient \[PUP\])~* Subject is currently utilizing primary FVIII prophylaxis~* Subjects anticipating elective surgery that may be planned to occur in the 6 months following study entry~* Treated with immunomodulatory therapy within 30 days prior to study entry or planned use for the duration of their study participation~* Participated in another investigational drug or device study within 30 days prior to study entry or planned participation for the duration of their study participation~* Subjects with a known hypersensitivity to hamster protein~* Significant hepatic or renal impairment (alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] \>5 x upper limit of normal \[ULN\], bilirubin \>2 mg/dL or serum creatinine \>1.25 x ULN)~* Prothrombin Time \>1.5 x ULN~* Platelet count \<80,000 / µL~* Pregnant or breastfeeding women~* Unwilling or unable to follow the terms of the protocol~* Any condition which may compromise the subject's ability to comply with and/or perform study-related activities or that poses a clinical contraindication to study participation, in the opinion of the Investigator or Sponsor

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Xyntha (Type: EXPERIMENTAL): This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prothrombin Complex Concentrate for Anticoagulant Reversal

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects on oral anticoagulation requiring rapid reversal due to acute bleeding or emergency surgery~* INR \> 2 at baseline~Key Exclusion Criteria:~* Acute thromboembolic event~* Treatment with any other investigational drug in the last 30 days before study entry~* Less than 2 weeks of stable oral anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low and High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Those who admit Kirsehir Ahi Evran University Hospital and is diagnosed with lateral epicondylitis,~* Participants with unilateral or bilateral lateral epicondylitis and pain and functional limitations due to this condition,~* who can read and write in Turkish,~* participant's admission participating in the study,~* participants who do not have exclusion criteria,~Exclusion Criteria:~* receiving any injection therapy to the elbow area in the last 3 months,~* participants with complaints less than 3 months(acute lateral epicondylitis)~* previously surgery on the elbow area,~* having a history of acute trauma or fracture in the elbow area,~* have local dermatological problems,~* have a local infection in the treatment area,~* those who are allergic to dextrose,~* with coagulation disorders or using anticoagulant drugs,~* with an autoimmune disease,~* with type 1 or type 2 diabetes mellitus,~* have unregulated hypertension,~* have immune dysfunction,~* with malignancy or diagnosed with a malignancy in the last 5 years,~* pregnancy or lactation,~* having cervical radiculopathy in the same extremity,~* with cognitive dysfunction,~* patients with paralysis in the same extremity,~* lack of cooperation due to cognitive impairment,~* participant's refusal to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- low dose dextrose arm (5% dextrose) (Type: ACTIVE_COMPARATOR): Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
- high dose dextrose arm (15% dextrose) (Type: ACTIVE_COMPARATOR): Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
- Isotonic saline arm (0.9% NaCl) (Type: ACTIVE_COMPARATOR): Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Body Temperature in Persons With Tetraplegia When Exposed to Cold

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* (1) Between 18 and 68 years of age;~* (2) Duration of injury ≥ 1 year; (2) Level of SCI C3-T1;~* (3) Euhydration (subjects will be instructed to avoid caffeine and alcohol, maintain normal salt and water intake, and avoid strenuous exercise for 24 hours prior to study)~Exclusion Criteria:~* (1) Known coronary heart, kidney, peripheral vascular or cerebral vascular disease;~* (2) High blood pressure;~* (3) Untreated thyroid disease;~* (4) Diabetes mellitus;~* (5) Acute illness or infection;~* (6) Dehydration;~* (7) Known allergies to midodrine hydrochloride;~* (8) Smoking;~* (9) Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: t

Study Arms:
- No Drug: Tetraplegia (Type: NO_INTERVENTION): Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room.
- No Drug: AB Controls (Type: NO_INTERVENTION): AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
- Drug (midodrine): Tetraplegia (Type: EXPERIMENTAL): Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* First or second relapse of a carcinoma of the ovary, the fallopian tubes or the peritoneal tissue histological proved.~* Interval without progress \> 6 months after the last administration of a salt of platinum(deck).~* Measurable Disease (according to the criteria RECIST 1.1) or an assessable disease according to CA-125 (according to the criteria of the GCIG).~* Satisfactory biological Balance sheet(Assessment), according to the following criteria:~  * Neutrophiles \> 1,5x 109/L, Plaques \> 100 x 109/L, Haemoglobin \> 9,0 g/dL.~ * Bilirubine \< 1.5 x LSN (Normal Superior Limit), transaminases and alkaline phosphatase \< 2. 5 x LSN.~ * Creatinin clearance \> 50 mL/min calculated according to the formula of Cockroft-Gault or MDRD.~* Performance status \< 2.~* Life expectancy of at least 12 weeks.~* Age \> 18 years.~* Capacity to follow the protocol.~* Consent signed before any procedure of inclusion.~* Membership in a national insurance scheme.~Exclusion Criteria:~* Tumor of mild histology or borderline, or malignant not epithelial tumor of the ovary, the fallopian tubes or the peritoneal tissue(eg. tumor of germ cells, tumor of the sexual cords and the stroma).~* History of abdominal or pelvic radiotherapy.~* Patient having received more than 2 lines of chemotherapy.~* Patient in 3rd relapse or more.~* History of another malignant tumor during the last 5 years, with the exception of a carcinoma in situ by the neck of the womb or by a squamous-cell carcinoma of the skin treated in a adequate way or any solid tumor considered in forgiveness completes without relapse for at least 5 years.~* Patients having a stubborn illness in the platinum, (eg. progress during the last chemotherapy or in 6 months following the last administration of platinum).~* Occlusive or sub-occlusive disease or presence of symptomatic intellectual metastases.~* Heart disorder dissuading the use of an anthracycline.~* Left venticular ejection fraction (LVEF) defined by MUGA/ECHO \< 50%.~* Wait presenting a severe infection.~* Woman old enough to procreate not using adequate contraceptive method.~* Concomitant disease not allowing a surgery and/or a chemotherapy.~* Pathology severe or concomitant not compatible with the taking of the study treatment or the participation of the patient in the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carboplatin and liposomal doxorubicin (Type: EXPERIMENTAL): carboplatin and liposomal doxorubicin in ovarian cancer in realapse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Mental Health Self-Directed Care Financing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* receiving mental health services at a Texas Department of State Health Services-funded mental health program~* diagnosis of serious mental illness consistent with federal Public Law 102-32~* assigned to a level of care eligible for a package of comprehensive clinical and rehabilitation services known as Service Package 3~* 18 years or older~* able to understand spoken English.~Exclusion Criteria:~* cognitive impairment~* homeless at time of recruitment~* history of violent behavior resulting in arrest and conviction in the past 10 years~* active substance use in the absence of substance use treatment~* enrollment in Medicare or dual beneficiary~* finances controlled by a third party (e.g., representative payee)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Self-directed care (Type: EXPERIMENTAL): Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
- Services as usual (Type: ACTIVE_COMPARATOR): Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete